Atipamezole: Difference between revisions
Jump to navigation
Jump to search
Kiran Singh (talk | contribs) (Created page with "{{Drugbox | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 458284977 | IUPAC_name = 4-(2-Ethyl-1,3-dihydroinden-2-yl)-3''H''-imidazole | image =Atipamezo...") |
m (Protected "Atipamezole": Bot: Protecting all pages from category Drug ([Edit=Allow only administrators] (indefinite) [Move=Allow only administrators] (indefinite))) |
||
| (One intermediate revision by one other user not shown) | |||
| Line 58: | Line 58: | ||
| molecular_weight = 212.290 g/mol | | molecular_weight = 212.290 g/mol | ||
}} | }} | ||
__Notoc__ | |||
{{SI}} | |||
{{CMG}} | |||
==Overview== | |||
'''Atipamezole''' (brand name Antisedan, [[Pfizer]]) is a synthetic [[Alpha-2 adrenergic receptor|α<sub>2</sub> adrenergic receptor]] [[adrenergic antagonist|antagonist]], indicated for the reversal of the sedative and analgesic effects of [[dexmedetomidine]] and [[medetomidine]] in dogs.<ref>[http://www.pfizerah.com/product_overview.asp?drug=AS&country=US&lang=EN&species=CN Pfizer Animal Health ANTISEDAN Product Overview<!-- Bot generated title -->]</ref> It has also been researched in humans as a potential [[Parkinson's disease#Treatment|anti-Parkinsonian]] drug.<ref name="pmid16389294">{{cite journal |author=Pertovaara A, Haapalinna A, Sirviö J, Virtanen R |title=Pharmacological properties, central nervous system effects, and potential therapeutic applications of atipamezole, a selective alpha2-adrenoceptor antagonist |journal=CNS Drug Reviews |volume=11 |issue=3 |pages=273–88 |year=2005 |pmid=16389294 |doi= 10.1111/j.1527-3458.2005.tb00047.x|url=}}</ref> | '''Atipamezole''' (brand name Antisedan, [[Pfizer]]) is a synthetic [[Alpha-2 adrenergic receptor|α<sub>2</sub> adrenergic receptor]] [[adrenergic antagonist|antagonist]], indicated for the reversal of the sedative and analgesic effects of [[dexmedetomidine]] and [[medetomidine]] in dogs.<ref>[http://www.pfizerah.com/product_overview.asp?drug=AS&country=US&lang=EN&species=CN Pfizer Animal Health ANTISEDAN Product Overview<!-- Bot generated title -->]</ref> It has also been researched in humans as a potential [[Parkinson's disease#Treatment|anti-Parkinsonian]] drug.<ref name="pmid16389294">{{cite journal |author=Pertovaara A, Haapalinna A, Sirviö J, Virtanen R |title=Pharmacological properties, central nervous system effects, and potential therapeutic applications of atipamezole, a selective alpha2-adrenoceptor antagonist |journal=CNS Drug Reviews |volume=11 |issue=3 |pages=273–88 |year=2005 |pmid=16389294 |doi= 10.1111/j.1527-3458.2005.tb00047.x|url=}}</ref> | ||
| Line 68: | Line 72: | ||
* [http://www.pfizerah.com/product_overview.asp?drug=AS&country=US&lang=EN&species=CN ANTISEDAN product information page (Pfizer Animal Health)] | * [http://www.pfizerah.com/product_overview.asp?drug=AS&country=US&lang=EN&species=CN ANTISEDAN product information page (Pfizer Animal Health)] | ||
[[Category:Imidazoles]] | [[Category:Imidazoles]] | ||
[[Category:Antidotes]] | [[Category:Antidotes]] | ||
[[Category:Drug]] | [[Category:Drug]] | ||
Latest revision as of 17:47, 18 August 2015
 | |
 | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| ATCvet code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C14H16N2 |
| Molar mass | 212.290 g/mol |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
|
WikiDoc Resources for Atipamezole |
|
Articles |
|---|
|
Most recent articles on Atipamezole Most cited articles on Atipamezole |
|
Media |
|
Powerpoint slides on Atipamezole |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Atipamezole at Clinical Trials.gov Clinical Trials on Atipamezole at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Atipamezole
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Atipamezole Discussion groups on Atipamezole Patient Handouts on Atipamezole Directions to Hospitals Treating Atipamezole Risk calculators and risk factors for Atipamezole
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Atipamezole |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Atipamezole (brand name Antisedan, Pfizer) is a synthetic α2 adrenergic receptor antagonist, indicated for the reversal of the sedative and analgesic effects of dexmedetomidine and medetomidine in dogs.[1] It has also been researched in humans as a potential anti-Parkinsonian drug.[2]
See also
- Detomidine, etc.
References
- ↑ Pfizer Animal Health ANTISEDAN Product Overview
- ↑ Pertovaara A, Haapalinna A, Sirviö J, Virtanen R (2005). "Pharmacological properties, central nervous system effects, and potential therapeutic applications of atipamezole, a selective alpha2-adrenoceptor antagonist". CNS Drug Reviews. 11 (3): 273–88. doi:10.1111/j.1527-3458.2005.tb00047.x. PMID 16389294.
External links
Categories:
- Pages with script errors
- CS1 maint: Multiple names: authors list
- Template:drugs.com link with non-standard subpage
- Drugs with non-standard legal status
- Articles with changed CASNo identifier
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Chemical pages without DrugBank identifier
- Drugboxes which contain changes to verified fields
- Drugboxes which contain changes to watched fields
- Imidazoles
- Antidotes
- Drug